Mergenhagen Kari A, Borton Angela R
Department of Pharmacy, Veterans Affairs Western New York Healthcare System, Buffalo, NY, USA
Department of Pharmacy, Erie County Medical Center, Buffalo, NY.
J Pharm Pract. 2014 Dec;27(6):545-53. doi: 10.1177/0897190014546114. Epub 2014 Sep 28.
Vancomycin earned notoriety for its tendency to cause nephrotoxicity shortly after it was introduced into practice, though the impurities responsible for historically significant rates of nephrotoxicity are of minimal concern today. Increasing usage of vancomycin has provided evidence that the drug itself can be nephrotoxic, but the exact mechanism by which this occurs has not been determined. Various studies have identified risk factors associated with development of vancomycin-associated nephrotoxicity, including total daily dose > 4 grams, trough levels > 20 mg/L, therapy exceeding 6 days, concurrent use of other nephrotoxic agents, preexisting renal disease, obesity, hypotensive episodes, and increasing severity of illness. Preventative strategies beyond risk assessment and therapeutic drug monitoring have shown little promise. Most cases of nephrotoxicity are reversible with discontinuation of vancomycin, but permanent renal damage can occur. This article is intended to serve as a practical review of vancomycin-associated nephrotoxicity, including historical context, risk factors, and common methods to evaluate and define renal dysfunction.
万古霉素在应用初期因易于导致肾毒性而声名狼藉,不过如今,以往造成显著肾毒性发生率的杂质已无需过多担忧。万古霉素使用的增多已证实该药物本身可导致肾毒性,但具体发生机制尚未明确。多项研究已确定与万古霉素相关性肾毒性发生相关的危险因素,包括每日总剂量>4克、谷浓度>20毫克/升、治疗超过6天、同时使用其他肾毒性药物、既往存在肾脏疾病、肥胖、低血压发作以及病情严重程度增加。除了风险评估和治疗药物监测之外,预防策略收效甚微。大多数肾毒性病例在停用万古霉素后可逆转,但也可能发生永久性肾损伤。本文旨在对万古霉素相关性肾毒性进行实用性综述,包括历史背景、危险因素以及评估和定义肾功能障碍的常用方法。